《公司業績》金沙中國(01928.HK)上半年虧損擴至7.6億美元
金沙中國(01928.HK)公布6月止六個月中期業績,錄得經調整物業EBITDA虧損1.2億元,相比2021年同期經調整物業EBITDA為2.34億美元。虧損由上年同期3.81億美元,擴至7.6億美元,每股虧損9.39美仙。
上半年,淨收益總額9.15億美元,減少43.5%。主要由於鄰近地區及澳門的COVID-19陽性病例增加,導致旅遊限制收緊令訪客減少。其中,娛樂場淨收益減少51.9%至11.8億美元。
6月止,擁有充足的流動資金,包括現金及現金等價物7.66億美元以及循環融資可動用的借款額10.4億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.